This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM.
The study is designed to follow each participant up to a maximum of 24 months.
Participants is starting avapritinib treatment at the HCP's discretion as part of their routine care (for ISM with moderate to severe symptoms inadequately controlled with symptomatic treatment) and in accordance with approved SmPC.
Participant with a potential increased risk for intracranial hemorrhage including those with a history of vascular aneurysm, intracranial hemorrhage, cerebrovascular accident within the prior year, or severe thrombocytopenia.
Participant who has previously taken avapritinib as a commercial drug or as part of a clinical study.
Adult participants with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, who are initiating treatment with commercial avapritinib according to the German approved label.
Other
Prospective
Avapritinib
DrugAvapritinib will be administered as an oral tablet.
Change From Baseline in Mastocytosis Control-quality of Life (MC-QoL) Questionnaire Score at Month 6
Socio-demographic Variable: Participant Age
Socio-demographic Variable: Participant Gender
Socio-demographic Variable: Participant Ethnicity
Socio-demographic Variable: Participant Race
Click on the lead sponsor to view all of their trials.
